Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database

• Published in: The journal of clinical endocrinology and metabolism 2006-06, Vol.91 (6), p.2047-2054
• Main Authors: Reiter, Edward O., Price, David A., Wilton, Patrick, Albertsson-Wikland, Kerstin, Ranke, Michael B.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biological and medical sciences; Body Height; Databases as Topic; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; Growth Hormone - therapeutic use; Human Growth Hormone - deficiency; Humans; Male; Medical sciences; Vertebrates: endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2005-2284

Context: Treatment with GH has been used to correct the growth deficit in children with GH deficiency (GHD). Although successful in increasing height velocity, such treatment often falls short of helping patients achieve full genetic height potential. Objective: This study set out to analyze near-final height (FH) data from a cohort of GH-treated children with idiopathic GHD. Design, Setting, and Participants: Of 1258 evaluable patients in the Pfizer International Growth Database (KIGS) with GHD, 980 were of Caucasian origin, and 278 were of Japanese origin; 747 had isolated GHD (IGHD), and 511 had multiple pituitary hormone deficiencies (MPHD). Main Outcome Measures: Near-FH, relation to midparental height, and factors predictive of growth outcomes were the main outcome measures. Results: Median height sd scores (SDS) at the start of treatment were −2.4 (IGHD) and −2.9 (MPHD) for Caucasian males and −2.6 (IGHD) and −3.4 (MPHD) for females, respectively; comparable starting heights were −2.9 (IGHD) and −3.6 (MPHD) for Japanese males and −3.3 (IGHD) and −4.0 (MPHD) for females, respectively. Corresponding near-adult height SDS after GH treatment were −0.8 (IGHD) and −0.7 (MPHD) for Caucasian males and −1.0 (IGHD) and −1.1 (MPHD) for females, respectively; and −1.6 (IGHD) and −1.9 (MPHD) for Japanese males and −2.1 (IGHD) and −1.8 (MPHD) for females, respectively. Differences between near-adult height and midparental height ranged between −0.6 and +0.2 SDS for the various groups, with the closest approximation to MPH occurring in Japanese males with MPHD. The first-year increase in height SDS and prepubertal height gain was highly correlated with total height gain, confirming the importance of treatment before pubertal onset. Conclusions: It is possible to achieve FH within the midparental height range in patients with idiopathic GHD treated from an early age with GH, but absolute height outcomes remain in the lower part of the normal range. Patients with MPHD generally had a slightly better long-term height outcome.